Satellos Bioscience (TSX:MSCL) EV-to-EBIT : -0.40 (As of May. 13, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Satellos Bioscience's Enterprise Value is C$6.36 Mil. Satellos Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-15.71 Mil. Therefore, Satellos Bioscience's EV-to-EBIT for today is -0.40.

The historical rank and industry rank for Satellos Bioscience's EV-to-EBIT or its related term are showing as below:

TSX:MSCL' s EV-to-EBIT Range Over the Past 10 Years
Min: -103.86 Med: 0 Max: 11.99
Current: -0.4

During the past 4 years, the highest EV-to-EBIT of Satellos Bioscience was 11.99. The lowest was -103.86. And the median was 0.00.

TSX:MSCL's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs TSX:MSCL: -0.40

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Satellos Bioscience's Enterprise Value for the quarter that ended in Dec. 2023 was C$8.91 Mil. Satellos Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-15.71 Mil. Satellos Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -176.28%.

Satellos Bioscience EV-to-EBIT Historical Data

The historical data trend for Satellos Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience EV-to-EBIT Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-1.94

-0.64

-0.57

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial									-0.64	-2.10	-0.50	-0.38	-0.57

Competitive Comparison of Satellos Bioscience's EV-to-EBIT

For the Biotechnology subindustry, Satellos Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Satellos Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's EV-to-EBIT falls into.

Satellos Bioscience EV-to-EBIT Calculation

Satellos Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	6.361	/	-15.713
	=	-0.40

Satellos Bioscience's current Enterprise Value is C$6.36 Mil.
Satellos Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-15.71 Mil.

Satellos Bioscience (TSX:MSCL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Satellos Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-15.713	/	8.91356
	=	-176.28 %

Satellos Bioscience's Enterprise Value for the quarter that ended in Dec. 2023 was C$8.91 Mil.
Satellos Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-15.71 Mil.

Satellos Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines